PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear...

29

Transcript of PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear...

Page 1: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 2: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 3: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 4: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 5: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 6: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 7: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 8: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 9: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 10: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 11: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 12: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 13: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 14: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 15: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 16: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 17: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 18: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 19: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 20: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health

Elevated preoperative MMP-9 impacts post-surgical outcomes

Altered mechanistic pathway in inflammationNormal mechanistic pathway

MMP-9

In vivo confocal microscopy in corneal haze

Altered basal inflammation can drive altered response post surgery

Shetty et al. ASCRS Innovation Lecture

Page 21: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 22: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 23: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 24: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 25: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 26: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 27: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 28: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health
Page 29: PowerPoint Presentation · DRY EYE TESTS Physiological Property Clinical Diagnostic Evaluation Tear production Schirmer test Staining with fluoroscein, rose Ocular epithelial health

ε υ χ α ρ ι σ τ ώ


The vestibular organ and the vestibulo-ocular reflex

The vestibular organ and the vestibulo-ocular reflex

Refractómetro - twilight, s.a. de c.v. · 2019. 4. 8. · La posición de línea de limite, vista a través del ocular se desviará de acuerdo a la temperatura cuando realice la

Refractómetro - twilight, s.a. de c.v. · 2019. 4. 8. · La posición de línea de limite, vista a través del ocular se desviará de acuerdo a la temperatura cuando realice la

Immunofluorescence Staining with μ-Slide 8 well

Immunofluorescence Staining with μ-Slide 8 well

Diagnostic approach to Disclosure ataxic child - AACPDM · Cogan ocular motor apraxia Hereditary sensory neuropathies ©AP NPCA: Diagnostic Approach 1. Brain MRI 2. α‐Fetoprotein

Diagnostic approach to Disclosure ataxic child - AACPDM · Cogan ocular motor apraxia Hereditary sensory neuropathies ©AP NPCA: Diagnostic Approach 1. Brain MRI 2. α‐Fetoprotein

Conditional deletion of AP-2β in mouse cranial neural crest …dmm.biologists.org/content/dmm/9/8/849.full.pdf · deletion of Tfap2b in NCCs resulted in post-natal ocular defects

Conditional deletion of AP-2β in mouse cranial neural crest …dmm.biologists.org/content/dmm/9/8/849.full.pdf · deletion of Tfap2b in NCCs resulted in post-natal ocular defects

Ocular Onchocerciasis The of Toll Like Receptor 2 and ...hss.ulb.uni-bonn.de/2010/2052/2052.pdf · Onchocerca volvulus is the causative agent of river blindness. River blindness is

Ocular Onchocerciasis The of Toll Like Receptor 2 and ...hss.ulb.uni-bonn.de/2010/2052/2052.pdf · Onchocerca volvulus is the causative agent of river blindness. River blindness is

MYASTHENIA GRAVIS: DIAGNOSIS AND TREATMENT · developed grade >III, as opposed to 31.3% of patients with grade at onset II or higher (p=0.038) Most (77.7%) of the patients with ocular

MYASTHENIA GRAVIS: DIAGNOSIS AND TREATMENT · developed grade >III, as opposed to 31.3% of patients with grade at onset II or higher (p=0.038) Most (77.7%) of the patients with ocular

2-chimaerin regulates a key axon guidance transition ... · The ocular motor system consists of three nerves which innervate six muscles to control eye movements. In humans, defective

2-chimaerin regulates a key axon guidance transition ... · The ocular motor system consists of three nerves which innervate six muscles to control eye movements. In humans, defective

OCULAR PHARMACOLOGY

OCULAR PHARMACOLOGY

Morphine alleviates myocardial ischemia/reperfusion injury in rats … · 2019-10-16 · Triphenyltetrazolium Chloride (TTC) Staining (1) Fresh myocardial tissues were placed into

Morphine alleviates myocardial ischemia/reperfusion injury in rats … · 2019-10-16 · Triphenyltetrazolium Chloride (TTC) Staining (1) Fresh myocardial tissues were placed into

Positivity assessment for intracellular cytokine staining ......ICS positivity Compare proportion of cells producing cytokine in antigen-stimulated samples vs. the unstimulated negative

Positivity assessment for intracellular cytokine staining ......ICS positivity Compare proportion of cells producing cytokine in antigen-stimulated samples vs. the unstimulated negative

Ocular Anatomy G. Wollstein, MD Associate Professor.

Ocular Anatomy G. Wollstein, MD Associate Professor.

Intracellular Cytokine Staining (ICS) Flow Cytometry Assay 1 Kent J. Weinhold, Duke CFAR Director November 6th, 2013 CFAR Director’s Meeting Flow Cytometry.

Intracellular Cytokine Staining (ICS) Flow Cytometry Assay 1 Kent J. Weinhold, Duke CFAR Director November 6th, 2013 CFAR Director’s Meeting Flow Cytometry.

JIM LR Apontador a laser • 0,8 μm, proteção ocular Interfaces • E/S analógicas e digitais • Alimentação: externa ou a bateria recarregável • Autonomia: ≥ 4 horas Ambiente

JIM LR Apontador a laser • 0,8 μm, proteção ocular Interfaces • E/S analógicas e digitais • Alimentação: externa ou a bateria recarregável • Autonomia: ≥ 4 horas Ambiente

Leica SR GSD Brochure, English - Cellularimaging · 2014-12-01 · YFP. Use existing primary and secondary antibodies, adapt the staining protocol and start benefi tting from the

Leica SR GSD Brochure, English - Cellularimaging · 2014-12-01 · YFP. Use existing primary and secondary antibodies, adapt the staining protocol and start benefi tting from the

Isis Pharmaceuticals - videonewswire.com 30, 2015 – Annual... · β-Thalassemia ISIS-DGAT2 Rx NASHPKK RG-125 NASH in Patients with Type 2 Diabetes ISIS-GSK4-L Rx Ocular Disease

Isis Pharmaceuticals - videonewswire.com 30, 2015 – Annual... · β-Thalassemia ISIS-DGAT2 Rx NASHPKK RG-125 NASH in Patients with Type 2 Diabetes ISIS-GSK4-L Rx Ocular Disease

Food Supplements enriched with Tridocosahexaenoina-AOX ...brudylab.net/english/assets/vademecum2018_eng.pdf · *** Authorized use until 3 months of first opening OCULAR INFLAMMATION

Food Supplements enriched with Tridocosahexaenoina-AOX ...brudylab.net/english/assets/vademecum2018_eng.pdf · *** Authorized use until 3 months of first opening OCULAR INFLAMMATION

KRAIBON...Compound Hard-ness (ShA) Density (g/cm³) Elongation at break (%) Tear strength (MPa) Rebound resilience (%) Damping tan-δ-peak (100Hz) Curing 120 C (min) Curing 140 C (min)

KRAIBON...Compound Hard-ness (ShA) Density (g/cm³) Elongation at break (%) Tear strength (MPa) Rebound resilience (%) Damping tan-δ-peak (100Hz) Curing 120 C (min) Curing 140 C (min)

Journal of Immunological Methods · 2016. 2. 5. · (APC-H7-clone MOPC-21, BD) as negative staining control for the CD107a surface stain (Supplementary Fig. 1). 2.3. α-GalCer activation

Journal of Immunological Methods · 2016. 2. 5. · (APC-H7-clone MOPC-21, BD) as negative staining control for the CD107a surface stain (Supplementary Fig. 1). 2.3. α-GalCer activation

Bacteria: Staining Techniques - PBworksevanpepper.pbworks.com/w/file/fetch/94175645/WCU Lab Slides 2015... · • Smear = a slide with microbes on it, ready to be stained 1) Label

Bacteria: Staining Techniques - PBworksevanpepper.pbworks.com/w/file/fetch/94175645/WCU Lab Slides 2015... · • Smear = a slide with microbes on it, ready to be stained 1) Label